<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818569</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000269</org_study_id>
    <nct_id>NCT02818569</nct_id>
  </id_info>
  <brief_title>Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic</brief_title>
  <official_title>Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The broad objective of this investigation is to assess the safety and efficacy of oral
      therapy with dexmedetomidine for the induction and maintenance of restful sleep.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sleep is a basic human function that occupies approximately one-third of our lives. Much of
      what is known about the benefits of sleep in humans has been obtained from studies of
      patients with insomnia, the most common sleep disorder with a reported prevalence of 10 to
      15%. Unfortunately, insomnia is an independent risk factor for acute myocardial infarction,
      coronary heart disease, heart failure, hypertension, diabetes, and death. More so, sleep
      disturbances lead to neurocognitive deficits such as delirium and psychosis. However, the
      principal medications (i.e. benzodiazepines, zolpidem) currently used to treat insomnia are
      associated with side effects such as daytime sedation, delirium, anterograde memory
      disturbance, and complex sleep-related behaviors. We recently found that a nighttime
      intravenous bolus administration of dexmedetomidine was associated with normal sleep
      architecture comprising of rapid eye movement (REM) and non-REM (N1, N2, N3) sleep, with
      improved next-day psychomotor vigilance performance compared to zolpidem. Presently,
      dexmedetomidine is only available in an intravenous formulation. The goal of this project is
      to develop dexmedetomidine, an alpha-2 receptor agonist, into an oral sleep therapeutic with
      a neurocognitive sparing profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Patients will receive both the oral dexmedetomidine intervention and placebo comparator in a randomized order.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic Stability (Phase I)</measure>
    <time_frame>Active study night, visit 3 or 4</time_frame>
    <description>Number of participants with (1) systolic blood pressure (SBP) &lt; 60 mmHg, diastolic blood pressure (DBP) &lt; 40 mmHg or decrease of SBP by ≥ 50 % from the baseline which is sustained over two consecutive minutes, (2) hypertension: SBP &gt; 180 mmHg, DBP &gt; 100 mmHg, or increase of SBP by ≥ 50 % from the baseline which is sustained over two minutes and, (3) bradycardia: heart rate (HR) &lt; 40 bpm or decrease by ≥ 50 % from the baseline sustained over two consecutive minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Polysomnography Sleep Quality (Phase II).</measure>
    <time_frame>Active study night, visit 3 or 4</time_frame>
    <description>Number of participants who had EEG features of natural sleep. Relative quantities of spindles and k-complexes were used to assess approximation to natural sleep.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance on the Psychomotor Vigilance Task (Phase II)</measure>
    <time_frame>Active study night, visit 3 or 4</time_frame>
    <description>The number of responses that were longer than 400 milliseconds (lapse 400).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on the Motor Sequence Task (Phase II)</measure>
    <time_frame>Active study night, visit 3 or 4</time_frame>
    <description>Number of participants with improved MST score after sleeping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Sleep Quality (Phase II)</measure>
    <time_frame>Active study night, visit 3 or 4</time_frame>
    <description>Self-reported sleep latency.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Sleep</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Oral Dexmedetomidine, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Oral Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Oral form</description>
    <arm_group_label>Oral Dexmedetomidine, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Oral Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Saline Placebo</description>
    <arm_group_label>Oral Dexmedetomidine, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Oral Dexmedetomidine</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-50

          -  Native English speaking

          -  ASA physical status classification P1 and P2 (stable chronic condition)

          -  Normal body habitus.

        Exclusion Criteria:

          -  Abnormal sleep habits

          -  Sleeping less than 5 hours each night

          -  Going to sleep before 9:00 PM or after 2:00 AM on a regular basis

          -  Waking up before 5:00 AM or after 10:00 AM on a regular basis.

          -  Takes medication that alters sleep, cognitive function, or both. -Has a history of a
             known neurological or psychiatric problem.

          -  Younger than 18 or older than 50 years of age.

          -  Known or suspected sleep disorder(s).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <results_first_submitted>August 15, 2019</results_first_submitted>
  <results_first_submitted_qc>October 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Oluwaseun Johnson-Akeju, MD, MMSc</investigator_full_name>
    <investigator_title>Assistant Professor in Anesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We are undecided.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02818569/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All 15 participants completed both arms (dexmedetomidine and placebo) for the study. After being randomized and completing the first arm, patients completed the alternative arm thereafter.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Dexmedetomidine, Then Placebo</title>
          <description>This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Oral Dexmedetomidine</title>
          <description>This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants who were either randomized to receive either Oral Dexmedetomidine or the placebo comparator initially.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemodynamic Stability (Phase I)</title>
        <description>Number of participants with (1) systolic blood pressure (SBP) &lt; 60 mmHg, diastolic blood pressure (DBP) &lt; 40 mmHg or decrease of SBP by ≥ 50 % from the baseline which is sustained over two consecutive minutes, (2) hypertension: SBP &gt; 180 mmHg, DBP &gt; 100 mmHg, or increase of SBP by ≥ 50 % from the baseline which is sustained over two minutes and, (3) bradycardia: heart rate (HR) &lt; 40 bpm or decrease by ≥ 50 % from the baseline sustained over two consecutive minutes.</description>
        <time_frame>Active study night, visit 3 or 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Dexmedetomidine</title>
            <description>Dexmedetomidine
Type: Oral</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Placebo Comparator
Type: Saline</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Stability (Phase I)</title>
          <description>Number of participants with (1) systolic blood pressure (SBP) &lt; 60 mmHg, diastolic blood pressure (DBP) &lt; 40 mmHg or decrease of SBP by ≥ 50 % from the baseline which is sustained over two consecutive minutes, (2) hypertension: SBP &gt; 180 mmHg, DBP &gt; 100 mmHg, or increase of SBP by ≥ 50 % from the baseline which is sustained over two minutes and, (3) bradycardia: heart rate (HR) &lt; 40 bpm or decrease by ≥ 50 % from the baseline sustained over two consecutive minutes.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP &lt; 60 mmHG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Polysomnography Sleep Quality (Phase II).</title>
        <description>Number of participants who had EEG features of natural sleep. Relative quantities of spindles and k-complexes were used to assess approximation to natural sleep.</description>
        <time_frame>Active study night, visit 3 or 4</time_frame>
        <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Dexmedetomidine</title>
            <description>Oral Dexmedetomidine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Saline
Saline Placebo: Saline Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Polysomnography Sleep Quality (Phase II).</title>
          <description>Number of participants who had EEG features of natural sleep. Relative quantities of spindles and k-complexes were used to assess approximation to natural sleep.</description>
          <population>All 15 Participants completed both arms of the study. After being randomized and completing a single arm, they proceeded to complete the second arm thereafter.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on the Psychomotor Vigilance Task (Phase II)</title>
        <description>The number of responses that were longer than 400 milliseconds (lapse 400).</description>
        <time_frame>Active study night, visit 3 or 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Oral Dexmedetomidine
Dexmedetomidine: Oral form</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Saline
Saline Placebo: Saline Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on the Psychomotor Vigilance Task (Phase II)</title>
          <description>The number of responses that were longer than 400 milliseconds (lapse 400).</description>
          <units>lapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Training (Before Sleep)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="5"/>
                    <measurement group_id="O2" value="6.5" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testing (After Sleep)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="15.5"/>
                    <measurement group_id="O2" value="12.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on the Motor Sequence Task (Phase II)</title>
        <description>Number of participants with improved MST score after sleeping.</description>
        <time_frame>Active study night, visit 3 or 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Oral Dexmedetomidine
Dexmedetomidine: Oral form</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Saline
Saline Placebo: Saline Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on the Motor Sequence Task (Phase II)</title>
          <description>Number of participants with improved MST score after sleeping.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Sleep Quality (Phase II)</title>
        <description>Self-reported sleep latency.</description>
        <time_frame>Active study night, visit 3 or 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>Oral Dexmedetomidine
Dexmedetomidine: Oral form</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Saline
Saline Placebo: Saline Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Sleep Quality (Phase II)</title>
          <description>Self-reported sleep latency.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="24.4"/>
                    <measurement group_id="O2" value="36.3" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Length of study conduction through visits 1-4</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>Oral Dexmedetomidine
Dexmedetomidine: Oral form</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator</title>
          <description>Saline
Saline Placebo: Saline Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Oluwaseun Johnson-Akeju</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-7200</phone>
      <email>ojohnsonakeju@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

